XML 34 R25.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Segment Information | 9 Months Ended
--- | ---
Sep. 30, 2022
Segment Reporting [Abstract] |
SEGMENT INFORMATION | 17. SEGMENT INFORMATION Our business operations (being the development, acquisition, manufacture and sale of products that improve the health and productivity of dairy and beef cattle) are described in Note 1. Pursuant to Codification Topic 280, Segment Reporting, we operate in the following two reportable business segments: i) Scours and ii) Mastitis. The Scours segment consists of the First Defense® product line. The core technology underlying the Scours segment is derived around polyclonal antibodies. The Mastitis segment includes our products, CMT and Re-Tain®. Re-Tain® is projected to be the driver of this segment when approved for sale. The core technology underlying the Mastitis segment is derived around polypeptide antimicrobials. The category we define as “Other” includes unallocated administrative and overhead expenses and other products. The significant accounting policies of these segments are described in Note 2. Product sales are the primary factor we use in determining our reportable segments. The governing regulatory authority (USDA for First Defense® or FDA for Re-Tain®) is also a factor in determining our reportable segments. Management monitors and evaluates segment performance from sales to net operating income (loss) closely. We are not organized by geographic region. No segments have been aggregated. The revenues and expenses allocated to each segment are in some cases direct and in other cases involve reasonable and consistent estimations by management. Each operating segment is defined as the component of our business for which financial information is available and evaluated regularly by our chief operating decision-maker in deciding how to allocate resources and in assessing performance. Our chief operating decision-maker is our President and CEO.
|  | During the Three-Month Period Ended September 30, 2022 |
|  | Scours |  |  | Mastitis |  |  | Other |  |  | Total |
Product sales |  | $ | 4,751,049 |  |  | $ | 44,976 |  |  | $ | — |  |  | $ | 4,796,025 |
Costs of goods sold |  |  | 2,898,897 |  |  |  | 45,441 |  |  |  | 5,636 |  |  |  | 2,949,974 |
Gross margin |  |  | 1,852,152 |  |  |  | (465 | ) |  |  | (5,636 | ) |  |  | 1,846,051 |
OPERATING EXPENSES: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product development expenses |  |  | 6,421 |  |  |  | 1,246,243 |  |  |  | 17,097 |  |  |  | 1,269,761 |
Sales and marketing expenses |  |  | 369,439 |  |  |  | 357,299 |  |  |  | — |  |  |  | 726,738 |
Administrative expenses |  |  | — |  |  |  | — |  |  |  | 466,342 |  |  |  | 466,342 |
Operating expenses |  |  | 375,860 |  |  |  | 1,603,542 |  |  |  | 483,439 |  |  |  | 2,462,841 |
NET OPERATING INCOME (LOSS) |  | $ | 1,476,292 |  |  | $ | (1,604,007 | ) |  | $ | (489,075 | ) |  | $ | (616,790 | )
|  | During the Three-Month Period Ended September 30, 2021 |
|  | Scours |  |  | Mastitis |  |  | Other |  |  | Total |
Product sales |  | $ | 5,033,428 |  |  | $ | 35,736 |  |  | $ | 81,009 |  |  | $ | 5,150,173 |
Costs of goods sold |  |  | 2,671,310 |  |  |  | 25,814 |  |  |  | 34,345 |  |  |  | 2,731,469 |
Gross margin |  |  | 2,362,118 |  |  |  | 9,922 |  |  |  | 46,664 |  |  |  | 2,418,704 |
OPERATING EXPENSES: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product development expenses |  |  | 17,326 |  |  |  | 1,001,354 |  |  |  | 28,818 |  |  |  | 1,047,498 |
Sales and marketing expenses |  |  | 496,010 |  |  |  | 160,408 |  |  |  | — |  |  |  | 656,418 |
Administrative expenses |  |  | — |  |  |  | — |  |  |  | 443,698 |  |  |  | 443,698 |
Operating expenses |  |  | 513,336 |  |  |  | 1,161,762 |  |  |  | 472,516 |  |  |  | 2,147,614 |
NET OPERATING INCOME (LOSS) |  | $ | 1,848,782 |  |  | $ | (1,151,840 | ) |  | $ | (425,852 | ) |  | $ | 271,090 |
|  | Scours |  |  | Mastitis |  |  | Other |  |  | Total |
Total Assets as of September 30, 2022 |  | $ | 18,678,408 |  |  | $ | 18,634,760 |  |  | $ | 9,088,393 |  |  | $ | 46,401,561 |
Total Assets as of September 30, 2021 |  | $ | 14,070,880 |  |  | $ | 19,310,110 |  |  | $ | 10,850,473 |  |  | $ | 44,231,463 |
Depreciation and amortization expense during the three-month period ended September 30, 2022 |  | $ | 302,235 |  |  | $ | 316,317 |  |  | $ | 15,688 |  |  | $ | 634,240 |
Depreciation and amortization expense during the three-month period ended September 30, 2021 |  | $ | 259,993 |  |  | $ | 344,554 |  |  | $ | 15,579 |  |  | $ | 620,126 |
Capital Expenditures during the three-month period ended September 30, 2022 |  | $ | 665,825 |  |  | $ | 21,032 |  |  | $ | 47,452 |  |  | $ | 734,309 |
Capital Expenditures during the three-month period ended September 30, 2021 |  | $ | 477,844 |  |  | $ | 193,561 |  |  | $ | 3,995 |  |  | $ | 675,400 |
|  | During the Nine-Month Period Ended September 30, 2022 |
|  | Scours |  |  | Mastitis |  |  | Other |  |  | Total |
Product sales |  | $ | 14,537,390 |  |  | $ | 118,237 |  |  | $ | 1,455 |  |  | $ | 14,657,082 |
Costs of goods sold |  |  | 7,870,420 |  |  |  | 104,092 |  |  |  | 25,967 |  |  |  | 8,000,479 |
Gross margin |  |  | 6,666,970 |  |  |  | 14,145 |  |  |  | (24,512 | ) |  |  | 6,656,603 |
OPERATING EXPENSES: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product development expenses |  |  | 23,025 |  |  |  | 3,331,311 |  |  |  | 90,128 |  |  |  | 3,444,464 |
Sales and marketing expenses |  |  | 1,127,676 |  |  |  | 1,069,801 |  |  |  | — |  |  |  | 2,197,477 |
Administrative expenses |  |  | — |  |  |  | — |  |  |  | 1,679,851 |  |  |  | 1,679,851 |
Operating expenses |  |  | 1,150,701 |  |  |  | 4,401,112 |  |  |  | 1,769,979 |  |  |  | 7,321,792 |
NET OPERATING INCOME (LOSS) |  | $ | 5,516,269 |  |  | $ | (4,386,967 | ) |  | $ | (1,794,491 | ) |  | $ | (665,189 | )
|  | During the Nine-Month Period Ended September 30, 2021 |
|  | Scours |  |  | Mastitis |  |  | Other |  |  | Total |
Product sales |  | $ | 13,529,846 |  |  | $ | 102,977 |  |  | $ | 166,306 |  |  | $ | 13,799,129 |
Costs of goods sold |  |  | 7,559,174 |  |  |  | 73,864 |  |  |  | 70,877 |  |  |  | 7,703,915 |
Gross margin |  |  | 5,970,672 |  |  |  | 29,113 |  |  |  | 95,429 |  |  |  | 6,095,214 |
OPERATING EXPENSES: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product development expenses |  |  | 24,892 |  |  |  | 2,837,830 |  |  |  | 215,948 |  |  |  | 3,078,670 |
Sales and marketing expenses |  |  | 1,279,673 |  |  |  | 334,324 |  |  |  | — |  |  |  | 1,613,997 |
Administrative expenses |  |  | — |  |  |  | — |  |  |  | 1,290,574 |  |  |  | 1,290,574 |
Operating expenses |  |  | 1,304,565 |  |  |  | 3,172,154 |  |  |  | 1,506,522 |  |  |  | 5,983,241 |
NET OPERATING INCOME (LOSS) |  | $ | 4,666,107 |  |  | $ | (3,143,041 | ) |  | $ | (1,411,093 | ) |  | $ | 111,973 |
|  | Scours |  |  | Mastitis |  |  | Other |  |  | Total |
Total Assets as of September 30, 2022 |  | $ | 18,678,408 |  |  | $ | 18,634,760 |  |  | $ | 9,088,393 |  |  | $ | 46,401,561 |
Total Assets as of September 30, 2021 |  | $ | 14,070,880 |  |  | $ | 19,310,110 |  |  | $ | 10,850,473 |  |  | $ | 44,231,463 |
Depreciation and amortization expense during the nine-month period ended September 30, 2022 |  | $ | 895,045 |  |  | $ | 946,878 |  |  | $ | 47,144 |  |  | $ | 1,889,067 |
Depreciation and amortization expense during the nine-month period ended September 30, 2021 |  | $ | 756,714 |  |  | $ | 1,062,703 |  |  | $ | 46,403 |  |  | $ | 1,865,820 |
Capital Expenditures during the nine-month period ended September 30, 2022 |  | $ | 2,050,107 |  |  | $ | 387,536 |  |  | $ | 47,452 |  |  | $ | 2,485,095 |
Capital Expenditures during the nine-month period ended September 30, 2021 |  | $ | 1,055,412 |  |  | $ | 840,675 |  |  | $ | 7,968 |  |  | $ | 1,904,055 |
|  | During the Year Ended December 31, 2021 |
|  | Scours |  |  | Mastitis |  |  | Other |  |  | Total |
Product sales |  | $ | 18,933,092 |  |  | $ | 143,280 |  |  | $ | 166,597 |  |  | $ | 19,242,969 |
Costs of goods sold |  |  | 10,411,936 |  |  |  | 99,957 |  |  |  | 75,147 |  |  |  | 10,587,040 |
Gross margin |  |  | 8,521,156 |  |  |  | 43,323 |  |  |  | 91,450 |  |  |  | 8,655,929 |
OPERATING EXPENSES: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product development expenses |  |  | 25,374 |  |  |  | 3,887,781 |  |  |  | 255,363 |  |  |  | 4,168,518 |
Sales and marketing expenses |  |  | 1,942,391 |  |  |  | 561,535 |  |  |  | — |  |  |  | 2,503,926 |
Administrative expenses |  |  | — |  |  |  | — |  |  |  | 1,726,100 |  |  |  | 1,726,100 |
Operating expenses |  |  | 1,967,765 |  |  |  | 4,449,316 |  |  |  | 1,981,463 |  |  |  | 8,398,544 |
NET OPERATING INCOME (LOSS) |  | $ | 6,553,391 |  |  | $ | (4,405,993 | ) |  | $ | (1,890,013 | ) |  | $ | 257,385 |
|  | During the Year Ended December 31, 2020 |
|  | Scours |  |  | Mastitis |  |  | Other |  |  | Total |
Product sales |  | $ | 15,072,446 |  |  | $ | 136,210 |  |  | $ | 133,548 |  |  | $ | 15,342,204 |
Costs of goods sold |  |  | 8,285,073 |  |  |  | 119,329 |  |  |  | 74,976 |  |  |  | 8,479,378 |
Gross margin |  |  | 6,787,373 |  |  |  | 16,881 |  |  |  | 58,572 |  |  |  | 6,862,826 |
OPERATING EXPENSES: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product development expenses |  |  | 106,393 |  |  |  | 4,022,712 |  |  |  | 225,522 |  |  |  | 4,354,627 |
Sales and marketing expenses |  |  | 2,119,289 |  |  |  | 48,610 |  |  |  | — |  |  |  | 2,167,899 |
Administrative expenses |  |  | — |  |  |  | — |  |  |  | 1,720,653 |  |  |  | 1,720,653 |
Operating expenses |  |  | 2,225,682 |  |  |  | 4,071,322 |  |  |  | 1,946,175 |  |  |  | 8,243,179 |
NET OPERATING INCOME (LOSS) |  | $ | 4,561,691 |  |  | $ | (4,054,441 | ) |  | $ | (1,887,603 | ) |  | $ | (1,380,353 | )
|  | Scours |  |  | Mastitis |  |  | Total |
Total Assets as of December 31, 2021 |  | $ | 22,442,944 |  |  | $ | 22,022,744 |  |  | $ | 44,465,688 |
Total Assets as of December 31, 2020 |  | $ | 18,416,157 |  |  | $ | 21,933,437 |  |  | $ | 40,349,594 |
Depreciation and amortization expense during the year ended December 31, 2021 |  | $ | 1,094,810 |  |  | $ | 1,374,171 |  |  | $ | 2,468,981 |
Depreciation and amortization expense during the year ended December 31, 2020 |  | $ | 1,002,360 |  |  | $ | 1,447,647 |  |  | $ | 2,450,007 |
Capital Expenditures during the year ended December 31, 2021 |  | $ | 1,655,866 |  |  | $ | 952,783 |  |  | $ | 2,608,649 |
Capital Expenditures during the year ended December 31, 2020 |  | $ | 3,456,307 |  |  | $ | 616,232 |  |  | $ | 4,072,539 |

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 34 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (e) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 26 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (d) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 15 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI https://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration